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Abstract
Using nanoparticles for therapy and imaging holds tremendous promise for the treatment of major
diseases such as cancer. However, their translation into the clinic has been slow because it remains
difficult to produce nanoparticles that are consistent ‘batch-to-batch’, and in sufficient quantities
for clinical research. Moreover, platforms for rapid screening of nanoparticles are still lacking.
Recent microfluidic technologies can tackle some of these issues, and offer a way to accelerate the
clinical translation of nanoparticles. In this Progress Article, we highlight the advances in
microfluidic systems that can synthesize libraries of nanoparticles in a well-controlled,
reproducible and high-throughput manner. We also discuss the use of microfluidics for rapidly
evaluating nanoparticles in vitro under microenvironments that mimic the in vivo conditions.
Furthermore, we highlight some systems that can manipulate small organisms, which could be
used for evaluating the in vivo toxicity of nanoparticles or for drug screening. We conclude with a
critical assessment of the near- and long-term impact of microfluidics in the field of
nanomedicine.
Nanomedicine is the application of nanotechnology to medicine, specifically involving the
use of engineered nanomaterials for therapy and diagnosis of major diseases such as cancer,
cardiovascular and infectious diseases1. The first generation of nanoparticles with
applications in medicine dates back to the 1970s, when drug-loaded nanoscale liposomes
were developed to deliver their cargo to diseased cells in a ‘Trojan horse’ fashion2. Since
then, a new generation of targeted drug delivery vehicles (for example, polymeric
nanoparticles)3, contrast agents (such as iron oxide nanoparticles)4, diagnostic tools5, and
antennas for photothermal therapy (for example, gold nanoparticles)6 have emerged. This is
driven in part by further understanding of the biology of diseased states, and by
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technological advances in imaging techniques and synthesis of novel biocompatible and
biodegradable materials7. Now, nanomedicine promises the precise delivery of drugs to
disease sites (such as tumours and atherosclerotic plaques) without off-target toxicities, and
the early detection of diseases using selective contrast agents and sensitive diagnostic tools8.
Nanoparticles are attractive in medicine because their surfaces can be chemically modified
for targeting specific disease tissues, or for in vivo stability. For therapy, drugs can be
encapsulated inside nanoparticles and released in a controlled manner over time. For
imaging, nanoparticles can provide higher contrast (for example, iron oxide nanoparticles
for magnetic resonance imaging) or higher brightness (for example, quantum dots (QDs) for
fluorescence imaging) than conventional small-molecule agents9. Despite these advantages
and several decades of research, only a handful of nanoparticles have received approval
from the US Food and Drug Administration. Examples include iron oxide nanoparticles for
magnetic resonance imaging (for example, Feridex and Resovist), liposomes encapsulating
the anticancer drug, doxorubicin, for chemotherapy (known as Doxil), and the protein-based
nanoparticle encapsulating paclitaxel for chemotherapy (called Abraxane)10.
In fact, translation of nanoparticles to the clinic has been slow compared with small-
molecule drugs, with the majority of nanoparticles not even reaching the point of in vivo
evaluation, and even fewer reaching clinical trials. This is due to a combination of factors. It
remains difficult to reproducibly synthesize batches of nanoparticles that have identical
properties and in sufficient quantities for clinical applications11. Moreover, knowledge on
the fate of nanoparticles at the body-, organ- and cell-level remains limited12; this makes
rational design of nanoparticles difficult and necessitates the use of screening-based
approaches for synthesis. Furthermore, there are few platforms that can rapidly evaluate the
biological behaviour of nanoparticles in vitro under conditions that can be correlated with
their performance in vivo11. For example, there is a need for high-throughput methods for
evaluating the binding and internalization of nanoparticles by cells, or the interaction of
nanoparticles with plasma proteins and the complement system, among others. Finally, there
is insufficient understanding of the biophysical and chemical interactions of nanoparticles
with proteins, membranes, DNA and organelles. These interactions could have either
beneficial or adverse outcomes13. It is expected that technologies tackling some of these
challenges could significantly accelerate the discovery and clinical translation of
nanomedicines.
Microfluidics — the science and technology of manipulating nanolitre volumes in
microscale fluidic channels — has impacted a range of applications, including biological
analysis, chemical synthesis, single-cell analysis and tissue engineering14. Building on its
origins in semiconductor technology and chemical separations, the expansion of
microfluidics has been driven by its ability to process small sample volumes and access
biologically relevant length scales and microscale transport phenomena. This expansion has
been largely facilitated by techniques, such as soft lithography, that enable rapid design and
prototyping of microfluidic devices using a variety of materials14. Recent advances and
innovations in microfluidics are expected to improve the synthesis of nanoparticles and
accelerate their transition to clinical evaluation (Fig. 1). Although many of these
microfluidic systems are still being developed, they have the potential to become widely
adopted because they are economical, reproducible, amenable to modifications and can be
integrated with other technologies15. In this Progress Article, we highlight some of these
technologies and discuss their impact on accelerating the clinical translation of
nanoparticles.
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Well-controlled synthesis of nanoparticles
Amphiphilic molecules such as block copolymers and lipids can self-assemble into
nanoparticles when they experience a change in solvent quality (for example, from organic
solvent to aqueous) (Fig. 2a). A common and flexible way to accomplish a change in solvent
quality is by mixing the solvent with the anti-solvent, where mixing time directly influences
the final size and size distribution of the nanoparticles formed16. If the mixing timescale,
τmix, is longer than the characteristic timescale for chains to nucleate and grow (τagg, ~10–
100 ms depending on the molecular weight of the chain), the nanoparticles begin to
assemble under varying degrees of solvent quality. This heterogeneous environment
prevents effective stabilization of the nanoparticles by the hydrophilic portion of the
amphiphilic molecule and facilitates their aggregation, leading to the formation of larger,
polydisperse nanoparticles. However, if τmix < τagg, particle self-assembly occurs primarily
when the solvent change is complete. This homogenous solvent environment for
nanoparticle assembly allows the hydrophilic portion of the molecule to stabilize the
nanoparticles more effectively, and this yields smaller nanoparticles with uniform size17.
Although conventional bulk mixing occurs at the timescale of seconds, in microfluidic
devices the mixing time of solvents is controllable and tunable from the millisecond to
microsecond scale (reaching τmix < τagg)16,18.
In recent years, several microfluidic systems that enable rapid mixing without the need of
external actuators, such as stirrers or electric fields, have been developed19. The most widely
used include flow-focusing mixers20, droplet mixers21 and those with micromixing
structures embedded inside the channel22. Flow focusing squeezes the solvent stream
between two anti-solvent streams, resulting in rapid solvent exchange via diffusion (Fig. 2b).
Droplets and three-dimensional microchannel geometries result in complex folding of fluid
flows, which can completely mix two or more streams in milliseconds (Fig. 2b). The
implementation of these mixing techniques for the formation of organic nanoparticles in
continuous flow has resulted in polymeric and lipid nanoparticles with tunable nanoparticle
size, narrower size distribution, higher drug loadings and greater batch-to-batch
reproducibility relative to those made with conventional bulk techniques23 (Fig. 2c).
Similarly, inorganic nanoparticles comprising transition metals such as gold, iron and
cadmium, among others, undergo self-assembly where metal solutes nucleate, grow and
agglomerate into nanoclusters (Fig. 2d)24. Obtaining narrow particle-size distribution
requires rapid nucleation followed by growth of nanoparticles to the desired size in the
absence of further nucleation, which can be accomplished by controlling the mixing time of
reagents, reaction temperature and reaction time25. In bulk, these parameters are difficult to
control, leading to uneven mixing, local temperature fluctuations and uncontrolled reaction
times25. In contrast, microfluidic devices allow for control over the mixing time by varying
solvent flow rates or channel geometry. Moreover, better heat transfer owing to large surface
areas enables better temperature control, preventing the formation of large temperature
gradients. Finally, as the channel length directly corresponds to the time taken by the
reactants to flow through it in continuous flow synthesis, the reaction time can be controlled
by tuning the channel length or by adding reagents at precise downstream locations during
the particle formation process to quench the reaction26.
Two-phase droplet mixers where reagents are encapsulated in droplets and separated by
inert fluids are commonly used for the synthesis of inorganic nanoparticles (Fig. 2e)27. In
this configuration, rapid mixing of the solutions occurs inside the droplets, which serve as
identical microscale reactors providing homogeneous conditions for nanoparticle nucleation
and growth. Both droplet-based and single-phase systems have been used to synthesize QDs
that exhibit narrow size distributions, which translates into sharper absorption peaks and
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better luminescence qualities27, with control over size to tune the absorption spectra28 (Fig.
2f). Finally, similar systems have been implemented in the controlled synthesis of gold
nanoparticles of defined size and shape, iron oxide nanoparticles with higher magnetization,
and QDs with controlled size and biocompatible coatings29.
Over the past four years, several examples showing the use of microfluidics for the synthesis
of nanoparticles with different size, shape and surface compositions have emerged30. At
present, there are microfluidic systems capable of characterizing the nanoparticle size and
stability following synthesis in a single platform31,32. Moreover, large numbers of distinct
nanoparticles can be obtained through combinatorial synthesis33, and production rates of
identical nanoparticles can be increased through parallelization or re-design of the
devices34,35. Similar to high-throughput synthesis of libraries of small molecules, these
advantages could potentially enable screening and optimization of libraries of nanoparticles
with distinct properties. One of the challenges in gene therapy, for example, is finding the
right formulation for delivering nucleic acids to specific sites in the body. By mixing
different precursors at varying ratios, microfluidic systems have enabled a one-step
combinatorial synthesis of libraries of polymeric and lipid nanoparticles that encapsulate
DNA and small-interfering RNA, respectively. Screening these libraries of nanoparticles has
helped identify superior formulations for gene transfection, compared with conventional
transfection agents such as lipofectamine 2000. Furthermore, using this method, potent
lipid-based small-interfering RNA formulations for in vivo delivery to the liver have also
been discovered33,34.
Evaluation and screening of nanoparticles
Another challenge in nanoparticle development is the lack of in vitro models capable of
predicting in vivo behaviour36. Conventionally, nanoparticles are evaluated in vitro using
cells cultured in well plates, which does not capture the complexity of nanoparticle–cell
interactions in vivo. For instance, a recent study showed that sedimentation of gold
nanoparticles in well plates could lead to misinterpretation of results, such as increased
nanoparticle uptake37. Microfluidics provides significant advantages over conventional
methods for cell and tissue culture by displaying structures and networks at relevant
physiological length scales, and by incorporating fluid flow and mechanical forces that bring
the cell-based assays a step closer to mimicking the in vivo microenvironment38 (Fig. 3a).
This is especially advantageous, for instance, when investigating the toxic effects related to
the cell uptake of nanoparticles. A recently developed microfluidic system for evaluating
QD toxicity on mouse fibroblasts revealed increased cell viability under flow conditions
compared with static incubation, possibly due to the absence of QD sedimentation39.
Recently, researchers have focused on developing biomimetic microfluidic technologies
capable of portraying organ-level functions on a chip, such as those observed in the lung,
liver and kidneys, among others38,40. For instance, microfluidic systems that reconstitute the
critical functional alveolar-capillary liquid/air interface of the human lung have been
recently fabricated by growing alveolar epithelial cells and microvascular endothelial cells
on different sides of a perforated silicone membrane. The membrane was pneumatically
actuated to mimic the physiological expansion–contraction motion due to breathing. It was
found that cyclic mechanical strain accentuates toxic and inflammatory responses in the lung
when exposed to silica nanoparticles, which could not have been observed with other
conventional in vitro systems41 (Fig. 3b). Using a similar design approach, a ‘gut-on-a-chip’
was developed by coating both sides of a membrane separating two microfluidic devices
with extracellular matrix and lined by human intestinal epithelial cells. It was demonstrated
that by subjecting the membrane to flow and cyclic strains similar to those encountered in
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the gut, villi-like structures were formed and the co-culture of the intestinal microbes was
made possible42 (Fig. 3c).
Expansion of these technologies to other organs, for instance ‘liver-on-a-chip’43, could lead
to platforms for evaluating and screening nanoparticle toxicity in organs where nanoparticles
tend to accumulate and toxicity is likely to be a major concern (for example, liver, spleen
and kidney). Although nanoparticles would still need to be evaluated in animals, such
microfluidic systems could take in vitro nanoparticle screening to a new level of utility by
selecting promising candidates with higher probabilities of success from a large pool of
nanoparticle formulations, and eliminating those that would otherwise have failed in larger
animal studies. Furthermore, coupling these technologies with microfluidic devices used for
nanoparticle synthesis opens the possibility of rapid combinatorial screening of a large
number of different nanoparticles under various conditions (for example, concentrations, pH
values, under the presence of specific proteins and so on).
Nanoparticles exhibiting promising results in vitro are subsequently evaluated in vivo,
which is considerably more expensive and resource intensive, especially in non-human
primates. Although most of the parameters, such as pharmacokinetics, biodistribution and
efficacy, are evaluated in mice and larger animals, tracking physiological effects of
nanoparticles on animal development could potentially be obtained using a large number of
smaller organisms. The zebrafish and Caenorhabditis elegans worms are well-known models
for studying fundamental mechanisms and progression of human diseases, and for drug
screening44. For example, the zebrafish was recently used as an in vivo model to develop a
hazard ranking for engineered nanoparticles based on their impact on mortality rate and
morphological defects in zebrafish embryos exposed to these materials45. However, current
methods for manipulating these organisms generally suffer from low throughput, low
automation and imprecise delivery of external stimuli46. To solve these challenges,
engineered microfluidic systems with dimensions comparable to small organisms and
containing valves and suction points have been developed. These systems enable precise
manipulation of these organisms with respect to placement and orientation for high-
throughput screening46,47 (Fig. 3d). Other microfluidic systems are being developed that are
capable of imaging dynamic cellular processes in small organisms, such as cell division and
migration, degeneration, aging and regeneration48. With such technologies in place, it might
be possible to use real-time microscopy to track physiological responses to fluorescently
labelled nanotherapeutics and nano-imaging agents, as well as assess the distribution and
efficacy of nanoparticles at both the organ and body level. Furthermore, real-time tracking
of nanoparticle-induced toxicity at different concentrations and conditions in small
organisms could enable rapid selection of nanoparticles (especially those made with novel
synthetic materials) that are more likely to be non-toxic in larger animals.
Future prospects
At present, the field of microfluidics applied to nanomedicine is still in its infancy. Although
nanoparticles have a relatively small footprint in the pharmaceutical industry, it is
anticipated that as these products bring in revenue, industry-led research and development
efforts would probably adopt technologies, such as microfluidics, to accelerate their
development. Nevertheless, microfluidic technologies, such as organ-on-a-chip and small-
animal screening, are likely to be adopted first for the screening of small-molecule drug
candidates, where the need for such tools is evident.
There are a few key directions at the intersection of microfluidics and nanomedicine that are
likely to be pursued in the near future (Table 1). Although the quantity of nanoparticles
synthesized by microfluidic devices is often in the micro- to milligram range, parallel and
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stackable microfluidic systems could continuously produce nanoparticles on the gram to
kilogram scale with the same properties as those prepared at the bench scale. Similarly, the
use of microfluidic platform technologies to reproducibly synthesize and screen libraries of
nanoparticles with different chemical compositions and/or physical and chemical properties
could potentially advance nanoparticle discovery analogously to how the high-throughput
screening of small molecules in medicinal chemistry advanced small-molecule discovery.
With respect to the design and development of novel nanoparticle constructs, the use of
microfluidics could enable the synthesis of nanoparticles with properties not accessible by
conventional synthesis, similar to what has already occurred for microparticle synthesis49.
Another avenue of future research will be the integration of different steps of nanoparticle
development into a single system (for example, nanoparticle synthesis characterization and
evaluation), together with feedback control through a combination of microfluidics, robotics
and automation, thus significantly cutting the time and cost of nanoparticle development.
Finally, mass-produced microfluidic devices and well-defined nanoparticle precursors can
aid in the synthesis of identical batches of nanoparticles with little to no variations
introduced by user handling. This could lead to the use and commercialization of
‘nanoparticle synthesis kits’ composed of calibrated devices that can reproducibly
synthesize a specific class of nanoparticle with well-defined properties for use as standards
in conventional toxicological assays. Considering the large number of nanoparticles being
made of novel synthetic materials or of unusual shapes, such standardization would be
highly useful for regulatory purposes, among others.
Microfluidic technologies are capable of accelerating the discovery and translation of
nanoparticles, and could serve as a tool for nanotherapeutics to reach a similar ‘tipping
point’ reached by genome sequencing in the past decade after high-throughput sequencing
technologies were developed50. Among all the microfluidic technologies, those developed
for synthesis and in vitro screening of nanoparticles have the highest probability of making
an impact in the near future (Table 1). Specifically, microfluidic synthesis may be adopted
as a second-generation manufacturing technology after the initial success of US Food and
Drug Administration-approved nanoparticles in cases where the advantages of microfluidic
synthesis are significant. Microfluidic synthesis may also be adopted as a screening tool to
identify optimal nanoparticles in academic and industrial research laboratories.
Alternatively, the impact of microfluidics might be observable in the medium- to long-term
future for nanoparticle characterization and in vivo evaluation. For nanoparticle
characterization, the use of microfluidics would probably increase once more-advanced
technologies are developed to characterize several nanoparticle properties (for example,
size, charge, surface composition and stability) in a single system. Similarly, in vivo
evaluation of nanoparticles in microfluidics would probably mature once both easily
adoptable microfluidic systems for manipulating small organisms and methods for
translating data obtained from these organisms to larger animals are developed.
Overall, the use of microfluidic technologies in nanomedicine brings exciting opportunities
to expand the body of knowledge in the field, advance the clinical translation of nano-based
therapeutics and imaging agents, and demonstrate innovative ways to develop other classes
of drugs.
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Figure 1. Nanoparticles in clinical development, steps for their translation (with average
timescales) and microfluidic methods (green boxes) that could improve or complement current
technologies
Synthesis is carried out in large reaction flasks, whereas microfluidic synthesis is carried out
at micro and nano length scales that allow for improved control over reaction conditions.
Characterization often involves taking a small sample of nanoparticles and measuring their
properties offline, whereas nanopores embedded in microfluidic devices allow for real-time,
in-line characterization. In vitro evaluation in plate wells produces a microenvironment far
from that in vivo, whereas continuous flow in microfluidic systems result in conditions
closer to those in vivo. In vivo evaluation in large animals is helpful for estimating the
pharmacology of nanoparticles. To complement these studies microfluidic systems could
enable real-time tracking of nanoparticles in large numbers of small organisms. Scale-up is
generally carried out in reactor vessels several times larger than benchtop flasks, whereas
parallelization of microfluidic channels can increase the production rate of nanoparticles
with properties identical to the one at bench scale.
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Figure 2. Microfluidic synthesis of nanoparticles
a, Schematic of the self-assembly mechanism of organic nanoparticles. On mixing with anti-
solvent, polymers (or lipids) are brought to the vicinity of each other (I) then nucleate (II),
subsequently aggregating into nanoparticles (III). b, Schematic of microfluidic synthesis of
organic nanoparticles by rapid mixing through hydrodynamic flow focusing (top) and
microvortices (bottom). Red and dark blue indicate organic and aqueous streams,
respectively, while pink and light blue indicate their degree of mixing. PEG, polyethylene
glycol; PLGA, poly(lactic-co-glycolic acid). c, Size distribution of polymeric nanoparticles
(top) and liposomes (bottom) prepared in microfluidics compared with bulk synthesis. In
both cases, narrower particle-size distributions are produced through microfluidics. d,
Schematic of the self-assembly mechanism of inorganic nanoparticles. Individual molecules
first nucleate (I and II), followed by aggregation of nuclei into nanoparticles (III). If the
reaction is not quenched or stabilized, nanoparticles tend to agglomerate into bulk material
(IV). A refers to individual molecules forming the nanoparticle, and An and Am refer to
nuclei formed of n and m number of A molecules, respectively. e, Microfluidic synthesis of
inorganic nanoparticles by rapid mixing through two-phase flow where reagents are
embedded in fluid droplets carried by an inert fluid. f, Top: sharp versus broad absorption
maximum of QDs synthesized in microchannels and bulk, respectively. Bottom: control of
the absorption spectra of QDs as function of reaction time. Figure reproduced with
permission from: a, ref. 16, © 2003 APS; b, Top: ref. 18, © 2008 ACS; Bottom: ref. 35, ©
2012 ACS; c, Top: ref. 18, © 2008 ACS; Bottom: ref. 23, © 2008 Springer; d, ref. 24, ©
2005 ACS; e, ref. 27, © 2004 RSC; f, Top: ref. 28, © 2010 Wiley; Bottom: ref. 27, © 2004
RSC.
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Figure 3. Microfluidic systems for in vitro evaluation and screening of nanoparticles
a, Schematic of nanoparticle sedimentation in conventional plates, which could result in
misinterpretation of results. In contrast, flow conditions in microfluidics provide a more-
accurate method for evaluating nanoparticles in vitro. b, Left: schematic of the lung-on-a-
chip that reconstitutes the critical functional alveolar-capillary interface of the human lung
through a stretchable membrane containing an epithelium layer on one side and an
endothelium layer on the other. Right: photograph of actual device. c, Top: schematic of the
gut-on-a-chip made by flexible, porous, extracellular matrix-coated membrane lined by gut
epithelial cells. The blue and brown arrows indicate two different streams of culture medium
separated by a membrane, entering the channel from the top and bottom, respectively.
Bottom: photograph of the gut-on-a-chip device made of polydimethylsiloxane elastomer. A
syringe pump was used to perfuse dyes (red and blue) for channel visualization. d, Left:
photograph of a dye-filled microfluidic system designed to handle C. elegans worms. Red,
control valve layer; yellow, flow layer; blue, immobilization layer. Scale bar, 1 mm. Right:
schematic showing load, capture, orient, immobilization and unload of the worm. Figure
reproduced with permission from: a, ref. 39, © 2010 AIP; b, ref. 41, © 2010 AAAS; c, ref.
42, © 2012 RSC; d, ref. 48, © 2010 NAS.
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Table 1
Advantages, disadvantages/challenges, stage of development and potential impact of microfluidic systems on
different steps in the clinical translation of nanoparticles.
Advantages Disadvantages/challenges Stage of development Potential impact
Synthesis • Tunable nanoparticle
size
• Narrower size
distribution
• Reproducible synthesis
• Potential for high-
throughput synthesis
and optimization of
nanoparticles
• Solvent and high-
temperature
incompatibility for
low-cost
polydimethylsiloxane
microchannels
• Higher costs and
complexities in the
fabrication of glass
and silicon
microdevices
***** Rapid
combinatorial,
controlled and
reproducible
synthesis of
libraries of
distinct
nanoparticles for
a
specific
application, and/
or
reference
nanoparticles for
toxicology
studies
Characterization • Label-free
characterization
• Potential for feedback
control and real-time
nanoparticle
optimization
• Current methods are
not applicable to all
classes of
nanoparticles
• Not all properties can
be characterized,
such as drug
encapsulation and
release, and signal-
to-noise ratio
* In-line rapid
characterization
and optimization
of
nanoparticles
In vitro • Biological conditions
closer to in vivo
microenvironments
• Potential for high-
throughout screening of
a large number of
nanoparticles at
different concentrations
• Higher costs and
complexities in the
fabrication and
operation compared
with well plates
• Might not be
reusable and if
reusable, it would be
difficult to keep
sterile
**** High-throughput
studies of
nanoparticle
toxicity, efficacy,
tumour
penetration and
organ
distribution,
using ‘organ-on-
a-chip’ systems
In vivo • Large number of
organisms could be
used for a single
measurement
• High-throughput
evaluation of toxicity
for a large number of
nanoparticles
• Lack of methods to
translate data from
small-scale
organisms to other
species
• Pharmacokinetics or
biodistribution
cannot be determined
** Real-time
tracking of the
distribution or
toxicity of
nanoparticles on
small-scale
organisms
Large-scale synthesis • Continuous synthesis
• Bench-scale to clinical-
scale reproducibility
• Parallelization allows
for tuning scale of
production
• Difficult to build
systems at low-cost
that are comparable
to a batch reactor
able to prepare grams
or kilograms of
nanoparticles
*** Synthesis of
nanoparticles for
human
administration
using
stackable parallel
microfluidic
units
(*****)
Rank: Most advanced in development
(*)
to least advanced in development, based on the amount of research carried out on each category, as well as the potential ease of adoption by
industry.
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